Skip to content

MIND-TIA: Markers in the Diagnosis of TIA

MIND-TIA: Markers in the Diagnosis of TIA - MIND-TIA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON38622
Enrollment
350
Registered
2013-09-05
Start date
2013-09-19
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mini-stroke Transient Ischemick Attack (TIA)

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Being adult (18 years and older) * Presenting to the GP with a new episode of symptoms suspected of TIA and the GP considering further investigations to confirm or exclude TIA at the TIA outpatient clinic. * A blood sample can be collected within 72 hours after onset of symptoms.

Exclusion criteria

Exclusion criteria: * The patient still has active symptoms or signs suspected of an ongoing ischemic stroke and immediate referral to the neurologist seems indicated. * Valid history taking is impossible because of severe cognitive impairment or insufficient knowledge of the Dutch language. * Patient with a life expectancy of

Design outcomes

Primary

MeasureTime frame
The main study parameter is the level of a set of biomarkers in a venous blood sample taken within 72 hours after onset of symptoms. Main study endpoint is the definite diagnosis of TIA (reference standard), which will be established by an expert panel consisting of three neurologists using all available diagnostic information including imaging of the brain and 6 months of follow-up.

Secondary

MeasureTime frame
Secondary parameters: Possible factors influencing doctor*s and patient*s delay Secondary endpoints: - Endpoints during 6months of follow-up: (ischemic) cerebrovascular events, (ischemic) cardiovascular events, and mortality. - Time delay (f.e. time to first of action of the patient, time to GP consultation)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)